Noile-Immune Biotech Overview
Get informed when a big investor buys or sells
+ Follow-21.09%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4893.T is -21.09%. That is above the Healthcare sector average of -75.84%. Investors often review this figure alongside Noile-Immune Biotech's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 4893.T currently prints -21.09% for ROE, while the sector average sits near -75.84%. That is roughly 72.2% above the sector mean. Large gaps often invite a closer look at Noile-Immune Biotech's growth, margins, and balance sheet.
Return on Equity shows how effectively Noile-Immune Biotech converts resources into returns. At -21.09%, 4893.T may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4893.T's ROE (-21.09%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Noile-Immune Biotech's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
